Quantifying treatment differences in confirmatory trials under non-proportional hazards

References

• P. Bauer and M. Posch, Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.H. Müller, statistics in medicine 2001; 20: 3741-3751, Statist. Med. 23 (2004), p. 1333.
   Google Scholar
• M. Brown, On the choice of variance for the log rank test, Biometrika 71 (1984), pp. 65–74. doi: 10.1093/biomet/71.1.65
   Web of Science ®Google Scholar
• T.R. Fleming and D.P. Harrington, A class of hypothesis tests for one and two sample censored survival data, Commun. Stat. Theory Methods 10 (1981), pp. 763–794. doi: 10.1080/03610928108828073
   Web of Science ®Google Scholar
• T.R. Fleming and D.P. Harrington, Counting Processes and Survival Analysis, Vol. 169, John Wiley & Sons, New York, NY, 2011.
   Google Scholar
• B. Freidlin and E.L. Korn, Methods for accommodating nonproportional hazards in clinical trials: Ready for the primary analysis? J. Clin. Oncol. 37 (2019), pp. 3455–3459. doi: 10.1200/JCO.19.01681
   PubMed Web of Science ®Google Scholar
• D.P. Harrington and T.R. Fleming, A class of rank test procedures for censored survival data, Biometrika 69 (1982), pp. 553–566. doi: 10.1093/biomet/69.3.553
   Web of Science ®Google Scholar
• B. Huang and P.F. Kuan, Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point, Pharm. Stat. 17 (2018), pp. 202–213. doi: 10.1002/pst.1846
   PubMed Web of Science ®Google Scholar
• B. Huang, L.J. Wei, and E.B. Ludmir, Estimating treatment effect as the primary analysis in a comparative study: Moving beyond p value, J. Clin. Oncol. 38 (2020), pp. 2001–2002. doi: 10.1200/JCO.19.03111
   PubMed Web of Science ®Google Scholar
• J. Irwin, The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, Epidemiol. Infect. 47 (1949), pp. 188–189.
   Google Scholar
• J.L. Jiménez, J. Niewczas, A. Bore, and C.F. Burman, A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching, preprint (2020), arXiv:2005.09213.
   Google Scholar
• J.L. Jiménez, V. Stalbovskaya, and B. Jones, Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects, Pharm. Stat. 18 (2019), pp. 287–303. doi: 10.1002/pst.1923
   PubMed Web of Science ®Google Scholar
• J.L. Jiménez, V. Stalbovskaya, and B. Jones, Response to comments on ‘properties of the weighted log-rank test in the design of confirmatory studies with delayed effects’, Pharm. Stat. 18 (2019), pp. 287–303.
   Google Scholar
• T. Karrison, Restricted mean life with adjustment for covariates, J. Amer. Statist. Assoc. 82 (1987), pp. 1169–1176. doi: 10.1080/01621459.1987.10478555
   Web of Science ®Google Scholar
• N.R. Latimer, C. Henshall, U. Siebert, and H. Bell, Treatment switching: Statistical and decision-making challenges and approaches, Int. J. Technol. Assess. Health Care 32 (2016), pp. 160–166. doi: 10.1017/S026646231600026X
   PubMed Web of Science ®Google Scholar
• J.W. Lee, Some versatile tests based on the simultaneous use of weighted log-rank statistics, Biometrics 52(2) (1996), pp. 721–725. doi: 10.2307/2532911
   Web of Science ®Google Scholar
• R.S. Lin and L.F. León, Estimation of treatment effects in weighted log-rank tests, Contemp. Clin. Trials Commun. 8 (2017), pp. 147–155. doi: 10.1016/j.conctc.2017.09.004
   PubMed Web of Science ®Google Scholar
• D. Magirr, Non-proportional hazards in immuno-oncology: Is an old perspective needed? preprint (2020), arXiv:2007.04767
   Google Scholar
• D. Magirr and C.F. Burman, Modestly weighted logrank tests, Stat. Med. 38 (2019), pp. 3782–3790. doi: 10.1002/sim.8186
   PubMed Web of Science ®Google Scholar
• D. Magirr, T. Jaki, F. Koenig, M. Posch, and R. K Hills, Sample size reassessment and hypothesis testing in adaptive survival trials, PLOS ONE 11 (2016), pp. e0146465. doi: 10.1371/journal.pone.0146465
   PubMed Web of Science ®Google Scholar
• K. Pak, H. Uno, D.H. Kim, L. Tian, R.C. Kane, M. Takeuchi, H. Fu, B. Claggett, and L.J. Wei, Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio, JAMA Oncol. 3 (2017), pp. 1692–1696. doi: 10.1001/jamaoncol.2017.2797
   PubMed Web of Science ®Google Scholar
• P. Royston and M.K. Parmar, The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Stat. Med. 30 (2011), pp. 2409–2421. doi: 10.1002/sim.4274
   PubMed Web of Science ®Google Scholar
• P. Royston and M.K. Parmar, Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome, BMC. Med. Res. Methodol. 13 (2013), pp. 2409.
   Web of Science ®Google Scholar
• M. Schemper, Cox analysis of survival data with non-proportional hazard functions, J. Roy. Stat. Soc. Ser. D 41 (1992), pp. 455–465.
   Google Scholar
• M. Schemper, S. Wakounig, and G. Heinze, The estimation of average hazard ratios by weighted cox regression, Stat. Med. 28 (2009), pp. 2473–2489. doi: 10.1002/sim.3623
   PubMed Web of Science ®Google Scholar
• D. Schoenfeld, The asymptotic properties of nonparametric tests for comparing survival distributions, Biometrika 68 (1981), pp. 316–319. doi: 10.1093/biomet/68.1.316
   Web of Science ®Google Scholar
• L. Tian, H. Jin, H. Uno, Y. Lu, B. Huang, K.M. Anderson, and L. Wei, On the empirical choice of the time window for restricted mean survival time, Biometrics (2020).
   Web of Science ®Google Scholar
• L. Tian, L. Zhao, and L. Wei, Predicting the restricted mean event time with the subject's baseline covariates in survival analysis, Biostatistics 15 (2014), pp. 222–233. doi: 10.1093/biostatistics/kxt050
   PubMed Web of Science ®Google Scholar
• L. Trinquart, J. Jacot, S.C. Conner, and R. Porcher, Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials, J. Clin. Oncol. 34 (2016), pp. 1813–1819. doi: 10.1200/JCO.2015.64.2488
   PubMed Web of Science ®Google Scholar
• H. Uno, B. Claggett, L. Tian, E. Inoue, P. Gallo, T. Miyata, D. Schrag, M. Takeuchi, Y. Uyama, L. Zhao, H. Skali, S. Solomon, S. Jacobus, M. Hughes, M. Packer, and Lee-Jen Wei, Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis, J. Clin. Oncol. 32 (2014), pp. 2380–2385. doi: 10.1200/JCO.2014.55.2208
   PubMed Web of Science ®Google Scholar
• H. Uno, J. Wittes, H. Fu, S.D. Solomon, B. Claggett, L. Tian, T. Cai, M.A. Pfeffer, S.R. Evans, and L.J. Wei, Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies, Ann. Intern. Med. 163 (2015), pp. 127–134. doi: 10.7326/M14-1741
   PubMed Web of Science ®Google Scholar
• G. Wassmer, Planning and analyzing adaptive group sequential survival trials, Biom. J. 48 (2006), pp. 714–729. doi: 10.1002/bimj.200510190
   PubMed Web of Science ®Google Scholar
• Z. Xu, B. Zhen, Y. Park, and B. Zhu, Designing therapeutic cancer vaccine trials with delayed treatment effect, Stat. Med. 36 (2017), pp. 592–605. doi: 10.1002/sim.7157
   PubMed Web of Science ®Google Scholar
• L. Zhao, B. Claggett, L. Tian, H. Uno, M.A. Pfeffer, S.D. Solomon, L. Trippa, and L. Wei, On the restricted mean survival time curve in survival analysis, Biometrics 72 (2016), pp. 215–221. doi: 10.1111/biom.12384
   PubMed Web of Science ®Google Scholar
• D.M. Zucker, Restricted mean life with covariates: Modification and extension of a useful survival analysis method, J. Amer. Statist. Assoc. 93 (1998), pp. 702–709. doi: 10.1080/01621459.1998.10473722
   Web of Science ®Google Scholar